Agomab Reports Half-Year 2026 Financials, Confirms Outlook, and Extends Cash Runway into 2029

summarizeSummary

Agomab reported half-year 2026 financials with €252 million in cash, extending runway into 2029, and confirmed its 2026 outlook with multiple clinical milestones expected in the coming months.

check_boxKey Events · Earnings and Guidance · AGMB

• Half-Year 2026 Financial Results

  Cash and cash investments totaled €252.0 million as of June 30, 2026, following a $208 million IPO in February 2026. R&D expenses were €23.0 million, G&A expenses €12.2 million (including IPO-related costs), and net loss was €31.0 million.

• Cash Runway Extended to 2029

  Management expects existing cash, including IPO proceeds, to fund operations and capital expenditures into the first half of 2029, removing near-term financing risk.

• Regulatory Alignment on NOV-ERA Study

  The FDA aligned on the Phase 2b NOV-ERA study design for ontunisertib in FSCD, including a novel primary endpoint of endoscopic passability. The protocol has cleared central IRB and received approvals in Canada and the UK.

• Upcoming Clinical Milestones

  Topline data from the OLE part of the STENOVA study with ontunisertib and from the Phase 1b IPF cohort with AGMB-447 are expected in the coming months. Initiation of the NOV-ERA Phase 2b and Phase 2 IPF trials is on track for the second half of 2026.

auto_awesomeAnalysis · AGMB · Life Sciences

Agomab's half-year update provides the first detailed look at its post-IPO financial position, with €252 million in cash extending the runway into 2029. The company confirmed alignment with the FDA on the NOV-ERA Phase 2b study design and reiterated that multiple clinical readouts and trial initiations are on track for the second half of 2026. The financials show a net loss of €31 million, driven by increased G&A from IPO-related costs, but the strong cash position removes near-term financing risk and supports the advancement of its fibro-inflammatory pipeline.